Site last updated:
July 2010
Cancer Services Forum currently has 713 registered members
The London Cancer New Drugs Group Meeting 2008
Share
Introduction
January 28th, 2008, saw the second London Cancer New Drugs Group (LCNDG) meeting played out at the Novotel Hotel, London: Commissioning cancer drugs and services—shared strategies for a common goal. Due to start at 10 am, the Nobel Suite Foyer was humming with conversation before the refreshments had been laid out—the reputation of the event as one offering a useful forum in which to debate key topics in commissioning and delivery of cancer services with key service personnel unusually drawn together in one room perhaps preceding it.
The objectives of the day were ambitious:
- To discuss the implications of the Cancer Reform Strategy for providers and commissioners of NHS services
- To explore how cancer drugs and supportive care can be effectively commissioned within a changing service environment
- To enhance consistent decision making and prioritisation within ethical and legal frameworks—establishing and sharing best practice in the managed entry of new cancer treatments
The aim of the next two issues of Cancer Services Forum is to provide an overview of the day’s content.
In this issue, a brief summary of the Cancer Reform Strategy will be followed by discussion of the document from a clinician’s and a commissioner’s perspective, contributed by Dr Alison Jones (Director of Cancer Services, University College London Hospitals NHS Foundation Trust) and Mr Dominic Conlin (Director of Strategic Commissioning, Croydon Primary Care Trust), respectively. The next issue will then explore in more detail the commissioning of cancer drugs, specifically prioritisation of new treatments from a public, ethical and legal perspective. First though, a few words on the LCNDG.
Copies of the presentations are available on request. Please contact csf@succinctcomms.com
Page 1 of 15
Discussion.